Letter to the Editor

We read with interest the article by Sondheimer et al. about an infant male with mitochondrial cardio-encephalopathy and CoQ10 deficiency due to a COQ4 mutation [@bb0005]. We have the following comments and concerns.

The newborn obviously had developed mitochondrial multiorgan disorder syndrome (MIMODS), manifesting in the brain (hypotonia, seizures, microcephaly, cortical T1-hyperintensities, cerebral lactic elevation), the ears (hypoacusis), the myocardium (cardiomyopathy), and the intestines (gastro-esophageal reflux) ([Table 1](#t0005){ref-type="table"}) [@bb0010]. Was the patient also screened for involvement of the endocrine organs, the bone marrow, the skin, and the lungs, also frequently involved in MIMODS?

How to interpret the cortical T1-hyperintensities? Was it due to bleeding, ischemia, inflammation, or due to the metabolic break-down? Was it the morphological equivalent of the seizures? Did it disappear after sufficient seizure control? Did the patient undergo lumbar puncture and cerebro-spinal (CSF) investigations? Was there any indication for elevated lactate, pleocytosis, or an immunological reaction to the metabolic defect in the CSF?

Nothing is reported about treatment with conezyme-Q (ubiquinone), which has been previously reported to be highly effective in single cases with coenzyme-Q deficiency [@bb0015]. Coenzyme-Q may be even effective in mitochondrial epilepsy [@bb0020]. Did the patient receive coenzyme-Q and in which dosage? Was any beneficial effect observed?

The patient developed epilepsy since day 7 after birth, being treated with phenobarbital, topiramate, and clobazam [@bb0005]. From phenobarbital it is well known that it can be mitochondrion-toxic [@bb0025]. Did the authors consider that deterioration of the clinical manifestations could have resulted from application of this antiepileptic drug?Table 1Manifestations of *COQ4* mutations.Table 1OrganManifestationReferenceCerebrumEpilepsy\[1, Chung 2015, Brea-Calvo 2015\]Central hypotonia\[1, Chung 2015, Brea-Calvo 2015\]Cerebellar atrophy\[Chung 2015, Brea-Calvo 2015\]Mental retardation\[Salviati 2012\]\*Brainstem hypoplasia\[Chung 2015\]Microcephaly[@bb0005]HeartCardiomyopathy\[1, Chung 2015\]Arrhythmia\[1, Brea-Calvo 2015\]Heart failure\[Brea-Calvo 2015\]IntestinesReflux[@bb0005]OtherLactic acidosis\[1, Chung 2015\]Dysmorphism\[Salviati 2012\]\*[^1]

We should be more comprehensively informed about the family history. Was the mutation assessed as de novo or inherited? Were any other first-degree family members affected? Did any of them carry the mutation of the index case? Were the parents consanguineous?

Overall, this interesting case requires supplementary clinical and genetic investigations.
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[^1]: The case described by Salviati et al. also carried a deletion of chromosome 9q34.13.
